[1] |
Schaub S, Hirsch HH, Dickenmann M, et al. Reducing immunosuppression preserves allograft function in presumptive and definitive polyomavirus-associated nephropathy[J]. Am J Transplant,2010,10(12): 2615-2623. doi: 10.1111/ajt.2010.10.issue-12
|
[2] |
Wu JK, Harris MT. Use of leflunomide in the treatment of polyomavirus BK-associated nephropathy[J].Ann Pharmacother,2008,42(11):1679-1685. doi: 10.1345/aph.1L180
|
[3] |
解俊杰,钱叶勇,石炳毅,等. 肾移植后BK病毒感染者实时荧光定量PCR检测[J]. 中国组织工程研究,2012,16(5):797-800. http://www.cnki.com.cn/Article/CJFDTOTAL-XDKF201205015.htmXie JJ, Qian YY, Shi BY, et al. BK virus infection detected by real-time fluorescent quantitative PCR method after renal transplantation[J].Chin J Tissue Eng Res, 2012,16(5):797-800. http://www.cnki.com.cn/Article/CJFDTOTAL-XDKF201205015.htm
|
[4] |
Kim H, Yang WS, Han DJ, et al. Clinical courses of renal transplant recipients with high BK viremia[J]. Transplant Proc, 2013, 45(8):2975-2979. doi: 10.1016/j.transproceed.2013.08.033
|
[5] |
Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients[J]. N Engl J Med,2002,347(7): 488-496. doi: 10.1056/NEJMoa020439
|
[6] |
Geddes CC, Gunson R, Mazonakis E, et al. BK viremia surveillance after kidney transplant: single-center experience during a change from cyclosporine-to lower-dose tacrolimus-based primary immunosuppression regimen[J]. Transpl Infect Dis,2011,13(2): 109-116. doi: 10.1111/tid.2011.13.issue-2
|
[7] |
Hirsch HH, Randhawa P, AST Infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation[J]. Am J Transplant,2013, 13(Suppl 4):179-188. http://cn.bing.com/academic/profile?id=1788698477&encoded=0&v=paper_preview&mkt=zh-cn
|
[8] |
Alméras C, Vetromile F, Garrigue V, et al. Monthly screening for BK viremia is an effective strategy to prevent BK virus nephropathy in renal transplant recipients[J]. Transpl Infect Dis,2011,13(2): 101-108. doi: 10.1111/tid.2011.13.issue-2
|
[9] |
Gonzalez S, Escobar-Serna DP, Suarez O, et al. BK virus nephropathy in kidney transplantation: an approach proposal and update on risk factors, diagnosis, and treatment[J]. Transplant Proc,2015, 47(6):1777-1785. doi: 10.1016/j.transproceed.2015.05.010
|
[10] |
Schachtner T, Stein M, Sefrin A, et al. Inflammatory activation and recovering BKV-specific immunity correlate with self-limited BKV replication after renal transplantation[J]. Transpl Int,2014, 27(3):290-301. doi: 10.1111/tri.2014.27.issue-3
|
[11] |
邓伟明,苗芸. 肾移植术后BK病毒相关性肾病的临床诊治研究进展[J]. 器官移植,2015,6(2):120-123,130. http://www.organtranspl.com/browse/detail/qkid/71/id/101.htmlDeng WM, Miao Y. Clinical research progress on diagnosis and treatment of BK virus-associated nephropathy after renal transplantation[J]. Organ Transplant,2015,6(2):120-123,130. http://www.organtranspl.com/browse/detail/qkid/71/id/101.html
|
[12] |
Halim MA, Al-Otaibi T, Gheith O, et al. Active management versus minimization of immunosuppressives of BK virus-associated nephropathy after a kidney transplant[J]. Exp Clin Transplant,2014,12(6):528-533. http://cn.bing.com/academic/profile?id=2337090942&encoded=0&v=paper_preview&mkt=zh-cn
|
[13] |
解俊杰,钱叶勇,石炳毅,等. 抢救性治疗对肾移植后BK病毒感染及其相关性肾病的临床效果[J]. 中华器官移植杂志,2013,34(2):105-109.Xie JJ, Qian YY, Shi BY, et al. Clinical observation of BK viremia and BK virus-associated nephropathy with rescuing therapy in renal transplant recipients[J]. Chin J Organ Transplant, 2013,34(2):105-109.
|
[14] |
Andrei G, Snoeck R, Vandeputte M, et al. Activities of various compounds against murine and primate polyomaviruses[J]. Antimicrob Agents Chemother, 1997,41(3):587-593. http://cn.bing.com/academic/profile?id=2107610513&encoded=0&v=paper_preview&mkt=zh-cn
|
[15] |
Zavos, G, Gazouli M, Psimenouet E, et al. Polyomavirus BK infection in Greek renal transplant recipients[J]. Transplant Proc, 2004,36(5): 1413-1414. doi: 10.1016/j.transproceed.2004.04.077
|
[16] |
Kuypers DR. Management of polyomavirus-associated nephropathy in renal transplant recipients [J]. Nat Rev Nephrol,2012,8(7):390-402. doi: 10.1038/nrneph.2012.64
|
[17] |
Hüttemann M, Shipkova M, Klett C, et al. Total and free plasma concentrations of the active metabolite of leflunomide in relation to therapeutic outcome in kidney transplant recipients with BK-virus nephropathy[J]. Transplant Proc,2013,45(4):1611-1613. doi: 10.1016/j.transproceed.2012.12.017
|
[18] |
Zaman RA, Ettenger RB, Cheam H, et al. A novel treatment regimen for BK viremia[J]. Transplantation, 2014, 97(11):1166-1171. doi: 10.1097/01.TP.0000441825.72639.4f
|
[19] |
Prince O, Savic S, Dickenmann M, et al. Risk factors for polyoma virus nephropathy[J]. Nephrol Dial Transplant,2009, 24(3):1024-1033. http://cn.bing.com/academic/profile?id=2002760966&encoded=0&v=paper_preview&mkt=zh-cn
|
[20] |
Schachtner T, Babel N, Reinke P. Different risk factor profiles distinguish early-onset from late-onset BKV-replication[J]. Transpl Int, 2015, 28(9):1081-1091. doi: 10.1111/tri.2015.28.issue-9
|